VYEPTI (Eptinezumab-jjmr)

Drug Overview

Basic Information

• Generic Name: Eptinezumab-jjmr
• Brand Name: VYEPTI
• Manufacturer: Lundbeck Seattle BioPharmaceuticals, Inc.
• Drug Class: Calcitonin gene-related peptide (CGRP) antagonist
• Antibody Type: Humanized IgG1 monoclonal antibody

FDA Approval History

• Initial Approval: February 21, 2020
• Approved Indications: Preventive treatment of migraine in adults
• Breakthrough Therapy Designation: Not applicable
• Orphan Drug Status: No

Available Formulations

• Strength: 100 mg/mL solution for intravenous infusion
• Presentation: Single-dose vial containing 100 mg in 1 mL
• Appearance: Clear to slightly opalescent, colorless to brownish-yellow solution

Pharmacology

Mechanism of Action

Eptinezumab is a humanized monoclonal antibody that binds specifically to CGRP ligand with high affinity (KD = 25 pM), preventing its interaction with CGRP receptors. CGRP is a neuropeptide that plays a crucial role in migraine pathophysiology by:

• Promoting vasodilation
• Facilitating pain transmission
• Inducing neurogenic inflammation
• Modulating central pain processing

By blocking CGRP, eptinezumab interrupts the cascade of events leading to migraine attacks.

Pharmacodynamics

• CGRP Binding: >90% inhibition achieved immediately post-infusion
• Duration of Effect: Sustained CGRP suppression for 3 months
• Blood-Brain Barrier: Limited penetration (<0.1% in CSF)
• Selectivity: No significant binding to other calcitonin family receptors

Pharmacokinetics

Absorption

• Route: Intravenous infusion only
• Bioavailability: 100% (IV administration)
• Cmax: Achieved at end of infusion

Distribution

• Volume of Distribution: 4.5-5.8 L
• Protein Binding: Not applicable for monoclonal antibodies
• Tissue Distribution: Primarily confined to vascular space

Metabolism

• Primary Pathway: Degradation by proteolytic enzymes
• CYP450 Involvement: None
• Metabolites: Small peptides and amino acids

Elimination

• Half-life: 27 days
• Clearance: 0.15 L/day
• Route of Elimination: Proteolytic degradation
• Renal Excretion: Negligible intact drug

Clinical Indications

FDA-Approved Indications

Prevention of Migraine in Adults

• Episodic migraine (4-14 headache days per month)
• Chronic migraine (≥15 headache days per month)

Clinical Criteria for Use

Appropriate Candidates:

• Adults ≥18 years with established migraine diagnosis
• ≥4 migraine days per month for ≥3 months
• Failed or intolerant to ≥2 oral preventive therapies
• Preference for quarterly administration
• Need for rapid preventive effect

Consider Alternative if:

• Pregnancy or breastfeeding
• Severe hypersensitivity to monoclonal antibodies
• Active serious infections
• Pediatric patients (<18 years)

Off-Label Uses

Currently, there are no well-established off-label uses. Ongoing research includes:

• Post-traumatic headache
• Medication overuse headache (as adjunct)
• Cluster headache prevention (investigational)

Clinical Efficacy

Pivotal Clinical Trials

PROMISE-1 Trial (Episodic Migraine)

Study Design: Phase 3, randomized, double-blind, placebo-controlled

• Population: 888 adults with episodic migraine
• Duration: 12 weeks with 52-week extension
• Arms: Placebo, eptinezumab 100 mg, eptinezumab 300 mg

Primary Endpoint: Change from baseline in monthly migraine days (MMDs) over weeks 1-12

• Placebo: -3.2 days
• Eptinezumab 100 mg: -3.9 days (p=0.018)
• Eptinezumab 300 mg: -4.3 days (p<0.001)

Key Secondary Endpoints:

• ≥50% responder rate at Week 12:
  • Placebo: 37.4%
  • 100 mg: 49.8% (p=0.009)
  • 300 mg: 56.3% (p<0.001)
• Migraine prevalence Day 1 post-infusion:
  • Placebo: 42.3%
  • 100 mg: 28.6% (p=0.004)
  • 300 mg: 27.8% (p=0.003)

PROMISE-2 Trial (Chronic Migraine)

Study Design: Phase 3, randomized, double-blind, placebo-controlled

• Population: 1,072 adults with chronic migraine
• Duration: 12 weeks with 52-week extension
• Arms: Placebo, eptinezumab 100 mg, eptinezumab 300 mg

Primary Endpoint: Change from baseline in MMDs over weeks 1-12

• Placebo: -5.6 days
• Eptinezumab 100 mg: -7.7 days (p<0.001)
• Eptinezumab 300 mg: -8.2 days (p<0.001)

Key Secondary Endpoints:

• ≥50% responder rate at Week 12:
  • Placebo: 39.3%
  • 100 mg: 57.6% (p<0.001)
  • 300 mg: 61.4% (p<0.001)
• Reduction in acute medication use days:
  • Significant reduction with both doses vs placebo

Long-Term Extension Studies

PREVAIL Study

• Duration: Up to 2 years
• Finding: Sustained efficacy with no evidence of tachyphylaxis
• Safety: No new safety signals identified
• Adherence: >90% completion rate

Comparative Effectiveness

While no head-to-head trials exist with other CGRP antagonists, indirect comparisons suggest:

• Onset: Faster than subcutaneous agents (Day 1 vs Week 1)
• Efficacy: Comparable MMD reduction to other CGRP antagonists
• Convenience: Quarterly dosing vs monthly for most alternatives
• Setting: Requires healthcare facility administration

Dosing and Administration

Recommended Dosing

• Standard Dose: 100 mg IV every 12 weeks
• Alternative Dose: 300 mg IV every 12 weeks for selected patients
• Loading Dose: Not required
• Missed Dose: Administer as soon as possible, then resume quarterly schedule

Dose Selection Considerations

100 mg dose appropriate for:

• Most patients initiating therapy
• Mild to moderate migraine frequency
• Cost-conscious situations

300 mg dose may be considered for:

• Severe chronic migraine (≥20 headache days/month)
• Inadequate response to 100 mg after 2 doses
• History of multiple preventive failures

Administration Procedures

Pre-Infusion Preparation

1. Remove vial from refrigerator 30 minutes before use
2. Inspect for particulate matter and discoloration
3. Do not shake vial
4. Use aseptic technique throughout

Dilution Instructions

1. Withdraw required dose (1 or 3 vials)
2. Dilute in 100 mL 0.9% Sodium Chloride
3. Gently invert bag to mix (do not shake)
4. Use within 4 hours at room temperature

Infusion Parameters

• Infusion Duration: 30 minutes
• Infusion Rate: 200 mL/hour
• Filter: Use 0.2 or 0.22 micron in-line filter
• Line Flush: Flush with 20 mL normal saline post-infusion

Special Population Dosing

• Renal Impairment: No dose adjustment required
• Hepatic Impairment: No dose adjustment required
• Elderly: No dose adjustment required
• Pediatric: Safety and efficacy not established

Safety Profile

Common Adverse Events (≥2% and > placebo)

1. Nasopharyngitis: 6-8%
2. Hypersensitivity reactions: 2-3%
3. Upper respiratory tract infection: 2-3%
4. Fatigue: 1-2%
5. Back pain: 1-2%
6. Arthralgia: 1-2%

Hypersensitivity Reactions

Incidence: 2.6% (100 mg) to 2.9% (300 mg) Manifestations:

• Rash, pruritus, flushing
• Urticaria (rare)
• Facial swelling (rare)
• Anaphylaxis (not reported in trials)

Management:

• Most reactions mild and self-limiting
• Antihistamines for mild reactions
• Discontinue infusion for severe reactions
• Have emergency medications available

Contraindications

• Serious hypersensitivity to eptinezumab or excipients

Warnings and Precautions

Hypersensitivity Reactions

• Can occur during or after infusion
• Monitor during and for 1 hour post-infusion
• Have resuscitation equipment available
• Consider premedication in high-risk patients

Immunogenicity

• Anti-drug antibody (ADA) development: 18-20%
• Neutralizing antibodies: 6%
• Impact on efficacy: Minimal in clinical trials
• No increased adverse events with ADAs

Pregnancy and Lactation

Pregnancy (Category: No FDA category assigned)

• Animal Data: No adverse effects at 50x human dose
• Human Data: Limited; registry ongoing
• Recommendation: Use only if benefit outweighs risk
• Registry: Patients encouraged to enroll in pregnancy registry

Lactation

• Excretion: Unknown if present in breast milk
• Consideration: IgG antibodies present in human milk
• Recommendation: Consider benefits vs risks

Drug Interactions

Pharmacokinetic Interactions

• CYP450: No interactions (not metabolized by CYP450)
• P-glycoprotein: No substrate or inhibitor activity
• Protein binding: Not applicable

Pharmacodynamic Interactions

• Other CGRP antagonists: Avoid combination (no added benefit)
• Acute migraine medications: No restrictions
• Other preventives: Can be used concurrently

Specific Medication Considerations

• Triptans: Safe to use for acute treatment
• NSAIDs: No interaction
• Opioids: No interaction (but discourage overuse)
• Botulinum toxin: Can be used together
• Oral preventives: No dose adjustments needed

Monitoring Parameters

Baseline Assessments

• Migraine history: Frequency, severity, triggers
• Previous treatments: Response and tolerability
• Comorbidities: Cardiovascular, psychiatric, neurologic
• Pregnancy status: For women of childbearing potential
• Baseline migraine diary: 1-3 months preferred

Efficacy Monitoring

• Monthly migraine days: Primary outcome
• Headache intensity: 0-10 scale
• Acute medication use: Days per month
• Functional impact: MIDAS or HIT-6 scores
• Quality of life: MSQ scores

Safety Monitoring

• Infusion reactions: During and 1 hour post
• Infection signs: Ongoing surveillance
• Injection site: Not applicable (IV only)
• Antibody formation: Not routinely tested

Follow-up Schedule

• Month 1: Phone/telehealth for early response
• Month 3: Before second infusion
• Quarterly: Coinciding with infusions
• Annual: Comprehensive assessment

Patient Counseling

Pre-Treatment Discussion

What to Expect

• Preventive (not acute) treatment
• Quarterly IV infusions at healthcare facility
• Effects may begin as early as Day 1
• Full benefit typically seen by 12 weeks
• Not a cure; reduces frequency and severity

Administration Process

• 30-minute infusion every 3 months
• Performed in clinic/infusion center
• Monitoring for 1 hour post-infusion
• Can resume normal activities afterward

Managing Expectations

• Response Rate: 50-60% achieve ≥50% reduction
• Timeline: Some benefit Day 1, maximum by Month 3
• Durability: Effects last throughout 3-month period
• Individual Variation: Response varies by patient

Side Effect Management

• Common side effects: Usually mild and temporary
• Nasopharyngitis: Symptomatic treatment
• Fatigue: Usually resolves within days
• Hypersensitivity: Report rash, itching, swelling immediately

When to Contact Healthcare Provider

• Signs of allergic reaction
• Severe or persistent side effects
• Worsening migraine pattern
• Pregnancy or planned pregnancy
• Need to reschedule infusion

Place in Therapy

Treatment Guidelines

American Headache Society (2021)

• Level A evidence for migraine prevention
• Consider for ≥4 headache days/month
• May be first-line or after oral preventive failure
• Choice among CGRP antagonists based on patient factors

American Academy of Neurology

• Established efficacy for episodic and chronic migraine
• Consider patient preferences for route and frequency
• Monitor response for 3-6 months

Comparison with Other CGRP Antagonists

Patient Selection Algorithm

Ideal Candidates for VYEPTI:

1. Rapid onset needed: Severe impact requiring quick relief
2. Adherence concerns: Quarterly supervised administration
3. Needle phobia: Single IV vs multiple SC injections
4. GI issues: Avoiding oral preventives
5. Previous CGRP failure: Different mechanism (if receptor antagonist failed)

Consider Alternatives if:

• Strong preference for home administration
• No access to infusion facilities
• Mild migraine with good oral response
• Cost/insurance barriers for IV therapy

Switching Considerations

From Oral Preventives:

• No washout needed for most
• Can overlap during transition
• Exception: MAO inhibitors (14-day washout)

From Injectable CGRP Antagonists:

• Can switch at next scheduled dose
• No washout period required
• Monitor for improved response

From Botulinum Toxin:

• Can use concurrently
• Space treatments by ≥2 weeks
• May have additive benefits

Special Populations

Elderly Patients (≥65 years)

• Pharmacokinetics: No clinically relevant changes
• Dosing: No adjustment needed
• Safety: Similar adverse event profile
• Considerations: Higher comorbidity burden; drug interactions with other medications

Renal Impairment

• Mild-Moderate: No dose adjustment
• Severe/ESRD: Limited data; use with caution
• Dialysis: Not removed by hemodialysis
• Monitoring: Standard safety monitoring

Hepatic Impairment

• All Stages: No dose adjustment required
• Metabolism: Not hepatically metabolized
• Child-Pugh C: No specific studies
• Monitoring: Standard safety monitoring

Pediatric Patients

• Current Status: Not approved <18 years
• Ongoing Studies: Trials in adolescents underway
• Safety Concerns: Theoretical impact on development
• Off-Label Use: Not recommended

Cardiovascular Disease

• Safety: No significant cardiovascular effects
• CGRP Role: Theoretical concern for vasodilation blockade
• Clinical Trials: Excluded recent MI/stroke
• Recommendation: Use with appropriate monitoring

Immunocompromised Patients

• Infection Risk: Theoretical increased risk
• Live Vaccines: No specific contraindication
• Monitoring: Vigilance for infections
• Cancer Patients: Limited data available

Storage and Handling

Storage Requirements

• Refrigeration: 2-8°C (36-46°F)
• Protection: Keep in original carton to protect from light
• Freezing: Do not freeze; discard if frozen
• Room Temperature: May store up to 25°C for maximum 7 days

Stability

• Unopened Vials: Until expiration date when refrigerated
• Room Temperature: 7 days maximum
• After Dilution: Use within 4 hours at room temperature
• Partially Used Vials: Discard (single use only)

Preparation Instructions

1. Visual Inspection: Check for particles or discoloration
2. Temperature: Allow to reach room temperature (30 minutes)
3. Mixing: Gently swirl; do not shake
4. Dilution: Add to 100 mL normal saline only
5. Filtration: Must use 0.2-0.22 micron filter

IV Compatibility

• Compatible: 0.9% Sodium Chloride
• Incompatible: Dextrose solutions, Lactated Ringer’s
• Y-site: Do not mix with other medications
• Line: Dedicated line preferred; flush if shared

Waste Disposal

• Follow institutional guidelines for biologic waste
• Dispose of vials, syringes, and IV materials properly
• No special environmental precautions required

Clinical Pearls

Optimizing Treatment Success

Patient Selection

• Best results in motivated patients with clear migraine diagnosis
• Consider baseline migraine frequency (better separation from placebo with higher frequency)
• Address medication overuse before initiation
• Set realistic expectations about prevention vs cure

Administration Tips

• Schedule infusions consistently (every 12 weeks)
• Consider premedication with antihistamine if prior reactions
• Ensure comfortable infusion setting
• Have rescue medications available

Monitoring Response

• Use validated tools (MIDAS, HIT-6, MSQ)
• Track both frequency and intensity
• Assess impact on acute medication use
• Consider 300 mg if partial response to 100 mg

Troubleshooting Common Issues

Inadequate Response

• Verify diagnosis and rule out secondary headaches
• Ensure adequate trial (minimum 2 infusions)
• Consider dose increase to 300 mg
• Address comorbidities and triggers
• May combine with oral preventive or Botox

Hypersensitivity Reactions

• Most are mild and don’t preclude continuation
• Premedicate with antihistamine/corticosteroid
• Slow infusion rate if needed
• Have emergency medications ready
• Document and report serious reactions

Insurance Challenges

• Provide detailed documentation of medical necessity
• Include failed therapies and contraindications
• Appeal denials with peer-to-peer review
• Consider manufacturer assistance programs
• Document functional impairment

Future Directions

Ongoing Research

• Pediatric and adolescent studies
• Combination therapy trials
• Biomarker development for response prediction
• Real-world effectiveness studies
• Head-to-head comparisons with other CGRP antagonists

Potential Expansions

• Home infusion programs
• Subcutaneous formulation development
• Other headache disorders
• Personalized dosing strategies